Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1Genitourinary 1

Conditions

Breast Neoplasms 1214Neoplasms 1024Carcinoma, Non-Small-Cell Lung 851Prostatic Neoplasms 683Colorectal Neoplasms 608Lung Neoplasms 575Neoplasm Metastasis 431Multiple Myeloma 420Leukemia, Myeloid, Acute 394Pancreatic Neoplasms 371Ovarian Neoplasms 359Melanoma 317Carcinoma, Hepatocellular 284Recurrence 274Squamous Cell Carcinoma of Head and Neck 272Brain Neoplasms 264Glioblastoma 245Head and Neck Neoplasms 241Stomach Neoplasms 236Precursor Cell Lymphoblastic Leukemia-Lymphoma 226Carcinoma, Renal Cell 225Lymphoma 221Triple Negative Breast Neoplasms 216Endometrial Neoplasms 207Hematologic Neoplasms 206Urinary Bladder Neoplasms 195Lymphoma, Non-Hodgkin 194Sarcoma 189Uterine Cervical Neoplasms 187Glioma 187

Interventions

olaparib 1liposomal doxorubicin 1durvalumab 1cediranib 1Topotecan 1Taxes 1Specimen Handling 1Paclitaxel 1Magnetic Resonance Spectroscopy 1Immunoglobulin G 1Doxorubicin 1Disulfides 1Contrast Media 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Mucinous Adenocarcinoma × 90 days × Clear all
NCT04739800 2026-05-29

Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents

National Cancer Institute (NCI)

Phase 2 Active not recruiting
120 enrolled 19 charts
GenitourinaryGynecologic

Fallopian Tube Mucinous Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡